Restricted Uses Without limiting the unsupported or prohibited use cases identified in the Stripe Identity Permitted Businesses list, you must not, and must not enable or allow any other party to:
(a) modify the Stripe Identity Services in any way, including by changing
Restricted Use Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adalimumab (Humira® / Biosimilar) NHSE Children with Severe Refractory Uveitis with onset in childhood (age 2 or more up to 18 or less) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adalimumab (Humira® / Biosimilar) ICB Weekly use for treatment of psoriasis in adults Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE TA146 does not cover weekly use RED Adalimumab (biosimilar) (Imraldi® / Amjevita®) ICB Peripheral spondyloarthritis - following use of 3 DMARDs, as per local pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adalimumab (biosimilar) various ICB weekly use for dose escalations in NICE-approved rheumatology indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adefovir Hepsera ® NHSE Hepatitis B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG165 - Oct 17 Double Red ADHD drugs - various (Various) ICB First-line use in children and adolescents with ADHD - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Double Red ADHD drugs - various (Various) ICB Use in pre-school children - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Afamelanotide Scenesse® NHSE erythropoietic protoporphyria Not commissioned. No NHS prescribing in primary or secondary care HST27 – July 2023 RED Afatinib ▼ (Giotrif® ▼) NHSE Treatment of epidermal growth factor receptor mutation-positive locally advanced or metastatic non- small-cell lung cancer - as per NICE TA 310 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA310 - April 2014 BLACK Afatinib ▼ (Giotrif® ▼) NHSE Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy - as per NICE TA 444 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA444 - May 17 RED Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) in new patients Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO) - as per NICE TA 305 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA305 - Feb 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Aflibercept (Zaltrap®) NHSE Treatment of metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (along with irinotecan and fluorouracil-based therapy) - as per NICE TA 307 - NICE Do Not Do Not commissioned. No NHS prescribing in primary or secondary care TA307 - Mar 14 RED Aflibercept (Eylea®) ICB Treatment of visual impairment caused by diabetic macular oedema (DMO) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA346 - Jul 15 RED Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema after branch retinal vein occlusion - as per NICE TA 409 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA409 - Sep 16 RED Aflibercept (Eylea®) ICB Treatment of visual impairment due to myopic choroidal neovascularisation in adults - as per NICE TA 486 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA486 - Nov 17 RED Aflibercept (Eylea®) ICB Treatment of Diabetic Macular Oedema (DMO) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration (AMD) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Aflibercept (switched to Ranibizumab (Lucentis®) (Eylea®) ICB Switching between products in the treatment of Wet Age-related Macular Degeneration (AMD) in previously treated patients who have not responded adequately to, or who have intolerance to aflibercept (Eylea®) - as per locally commissioned pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NG82 - Jan 18 RED Agalsidase alfa and beta (Replagal® (alpha) / Fabrazyme® (beta)) NHSE Fabry disease (α-galactosidase A deficiency) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Agomelatine (Valdoxan®) ICB 4th line use in depression where other treatments have failed or not been tolerated (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA231 - Sep 11 RED Albumin bound paclitaxel Abraxane ® NHSE with gemcitabine for untreated metastatic pancreatic cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA476 - Sep 17 RED Albutrenpenon acog alfa (Idelvion) NHSE Haemophilia B - as per NHS England policy SSC1652 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. DM Albutropin NHSE Adult onset growth hormone deficiency . Discontinued Medicines NICE has not issued any guidance. RED Aldesleukin (Proleukin) NHSE Cancer - metastatic renal cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alectinib (Alecensa®) NHSE Untreated ALK-positive advanced non-small-cell lung cancer - as per NICE TA 536 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA536 - Aug 18 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alectinib ▼ (Alecensa® ▼) NHSE Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - as per NICE TA 438 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA438 - Mar 17 RED Alemtuzumab (Lemtrada®) NHSE Chronic lymphocytic leukaemia (CLL) - as per NHS England policy 2013 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab (Lemtrada®) NHSE Pre-transplant immunosuppression Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab (MabCampat h®) NHSE Behcet's syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab ▼ (Lemtrada® ▼) NHSE Treatment of adults with relapsing- remitting multiple sclerosis (RRMS) - as per NICE TA 312 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA312 – May 2014, updated May 2024 Double Red Alendronate / Vitamin D3 combination (Fosavance® ) ICB Treatment of post menopausal osteoporosis in women at risk of vitamin D deficiency Not recommended for routine use NICE has not issued any guidance. GREEN Alendronic acid (sodium alendronate) (Generics available) ICB Secondary prevention of osteoporotic fragility fractures in postmenopausal women - as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA161 - Oct 08 GREEN Alendronic acid (sodium alendronate) (Generic available) ICB Primary prevention of osteoporotic fragility fractures in postmenopausal women as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA464 - Aug 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Alfacalcidol (AlfaD®, One- Alpha®) ICB Preparation for hyperparathyroidectomy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. RED Alglucosidase alfa (Myozyme®) NHSE Pompe disease (a lysosomal storage disorder caused by deficiency of acid alpha- glucosidase) - as per NHS England Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Alimemazine (Trimeprazine) (Generics) ICB Sedative in children / general antihistamine Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. RED Alipogene tiparvovec (Glybera®) NHSE (Gene therapy treatment for ) Lipoprotein lipase deficiency - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alirocumab ▼ (Praluent® ▼) ICB Treating primary hypercholesterolaemia and mixed dyslipidaemia - as per NICE TA 393 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA393 - Jun 16 BLACK Aliskiren ▼ (Rasilez® ▼) ICB Treatment of essential hypertension - as per NICE CG 127 Not commissioned. No NHS prescribing in primary or secondary care CG127 - Sep 11 Double Red Alisporivir ((aka Debio 025 / DEB025 / UNIL-025)) NHSE Viral Hepatitis C - as per NHSE policy Not recommended for routine use NICE has not issued any guidance. RED Alitretinoin (Toctino®) ICB Treatment of severe chronic hand eczema - as per NICE TA 177 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA177 - Aug 09 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alpelisib Piqray® NHSE with fulvestrant for treating hormone-receptor positive, HER2- negative, PIK3CA-positive advanced breast cancer (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA652 – October 2020 RED Alpelisib Piqray® NHSE with fulvestrant for treating hormone receptor-positive, HER2- negative, PIK3CA-mutated advanced breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA816 – August 2022 Double Red Alpha blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 . Not recommended for routine use CG101 - Jul 10 RED Alpha- mannosidase - recombinant human (Lamazym®) NHSE Alpha Mannosidase deficiency - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Alprostadil cream (Vitaros®) ICB Erectile dysfunction (as per SLS conditions only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. RED Alteplase (Actilyse®) ICB Treatment of acute ischaemic stroke - as per NICE TA 264 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA264 - Sep 12 Double Red Amantadine Hydrochloride (Lysovir®) ICB Treatment and prophylaxis of influenza Not recommended for routine use TA168 - Feb 09 RED Ambrisentan (Volibris® ▼) NHSE Pulmonary Arterial Hypertension - specialist centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Amifampridine (phosphate) ▼ (Firdapse® ▼) NHSE Treatment of myasthenias - Xxxxxxx-Xxxxx syndrome - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Amikacin - liposomal for inhalation (Arikace®) NHSE Gram-negative bacterial infection in Cystic Fibrosis . Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.
Restricted Use of Confidential Information (a) Each Receiving Party acknowledges the confidential and proprietary nature of the Confidential Information of the Disclosing Party and agrees that such Confidential Information (i) shall be kept confidential by the Receiving Party; (ii) shall not be used for any reason or purpose other than to evaluate and consummate the Contemplated Transactions; and (iii) without limiting the foregoing, shall not be disclosed by the Receiving Party to any Person, except in each case as otherwise expressly permitted by the terms of this Agreement or with the prior written consent of an authorized representative of Seller with respect to Confidential Information of Seller(each, a "Seller Contact") or an authorized representative of Buyer with respect to Confidential Information of Buyer (each, a "Buyer Contact"). Each of Buyer and Seller shall disclose the Confidential Information of the other party only to its Representatives who require such material for the purpose of evaluating the transactions contemplated herein and are informed by Buyer or Seller, as the case may be, of the obligations of this Article 12 with respect to such information. Each of Buyer and Seller shall (iv) enforce the terms of this Article 12 as to its respective representatives; (v) take such action to the extent necessary to cause its representatives to comply with the terms and conditions of this Article 12; and (vi) be responsible and liable for any breach of the provisions of this Article 12 by it or its representatives.
(b) Unless and until this Agreement is terminated, Seller shall maintain as confidential any Confidential Information (including for this purpose any information of Seller of the type referred to in Sections 12.l(a)(i), (ii) and (iii), whether or not disclosed to Buyer) of the Seller or Shareholders relating to any of the Assets or the Assumed Liabilities.
(c) From and after the Closing, the provisions of Section 12.2(a) above shall not apply to or restrict in any manner Buyer's use of any Confidential Information of the Seller relating to any of the Assets or the Assumed Liabilities.
Unauthorized Use or Disclosure The Contractor shall notify COMMERCE within five (5) working days of any unauthorized use or disclosure of any confidential information, and shall take necessary steps to mitigate the harmful effects of such use or disclosure.
Employee Access Employees are entitled to read and review their personnel file and, without limiting the generality of the foregoing, shall be entitled to inspect their performance evaluations, written censures, letters of reprimand, and other adverse reports. Upon request, employees shall be given copies of all such pertinent documents. The Employer further agrees that no personal files or documents on employees shall be kept outside of the personnel file, apart from payroll or health services files.
Passwords and Employee Access Provider shall secure usernames, passwords, and any other means of gaining access to the Services or to Student Data, at a level suggested by Article 4.3 of NIST 800-63-3. Provider shall only provide access to Student Data to employees or contractors that are performing the Services. Employees with access to Student Data shall have signed confidentiality agreements regarding said Student Data. All employees with access to Student Records shall pass criminal background checks.
Limited Use Each Party agrees it shall not, without the prior written consent of the other Party or as permitted by the terms and conditions of this Agreement, do any of the following: (i) disclose any Confidential Information to any third party; (ii) permit any third party access to such Confidential Information; or (iii) use Confidential Information for any purpose other than collecting debt on the Referred Account s referred to Agency by Client.
Geographic Restrictions The owner of the Website is based in the State of New York in the United States. We provide this Website for use only by persons located in the United States, and it may only be available to people located in the United States. We make no claims that the Website or any of its content is available or appropriate outside of the United States. Access to the Website may not be legal by certain persons or in certain countries.
Permitted Uses BA shall use Protected Information only for the purpose of performing BA’s obligations under the Contract and as permitted or required under the Contract and Addendum, or as required by law. Further, BA shall not use Protected Information in any manner that would constitute a violation of the Privacy Rule or the HITECH Act if so used by CE. However, BA may use Protected Information as necessary (i) for the proper management and administration of BA;
